Clinical trials: Biological Therapy
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Moderate to Severe Rheumatoid Arthritis
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
- Trial name
- ROCkIES (NCT01927757)
- Testing
- Etanercept, Methotrexate
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 90 people
- Sponsor
- Amgen
Psoriatic Arthritis (PsA)
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE2 (NCT03671148)
- Testing
- Risankizumab
- Where
- 138 sites in United States, Argentina and 23 more
- Volunteers
- 444 people
- Sponsor
- AbbVie
Infections, Rotavirus
Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines
The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given prophylactically.
- Trial name
- NCT00370318
- Testing
- 10 valent pneumococcal conjugate vaccine, Infanrix Hexa, Rotarix
- Where
- 10 sites in Czechia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Emerging Infectious Diseases and Their Treatments
Biological Collection on Emerging Infectious Diseases and Their Treatments
Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs).
- Trial name
- COMETE (NCT07674550)
- Where
- France
- Volunteers
- 5,300 people
- Sponsor
- University Hospital, Toulouse
Prostate Cancer
Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
The study aims to identify potential urine marker metabolites as predictive or prognostic markers for treatment outcomes in patients with prostate cancer.
- Trial name
- NCT03237026
- Testing
- No intervention required
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- National Taiwan University Hospital
Asthma, Aspirin-Induced, Chronic Rhinosinusitis With Nasal Polyps
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
Primary objective: to investigate the efficacy of Mepolizumab 100 milligram (mg) every month compared to placebo in reducing validated Sinonasal Outcome Test -22 score and on reducing endoscopic Nasal Polyp Score.
- Trial name
- AirGOs-biol (NCT04823585)
- Testing
- Mepolizumab
- Where
- Finland
- Volunteers
- 95 people
- Sponsor
- Helsinki University Central Hospital
Gastric (Stomach) Cancer, Biological Therapy
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
This project employs a prospective, double-blind, randomized controlled trial methodology to comparatively analyze the safety and survival outcomes of human umbilical cord blood RAK cells applied in advanced gastric cancer.
- Conditions
- Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy
- Trial name
- RAK in GC (NCT07212933)
- Testing
- RetroNectin active Killer cells, TAS-102 (trifluridine and tipiracil, Lonsurf®)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Intrauterine Adhesion
The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis
Asherman's syndrome is characterized by the presence of intrauterine adhesions (IUA) as well as symptoms such as amenorrhea, hypomenorrhea, pelvic pain, and infertility.
- Trial name
- NCT03351205
- Testing
- disposable balloon uterine stent, dried biological amnion graft, estradiol valerate tablets+dydrogesterone tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Obstetrics and Gynecology Hospital
Osteoarthritis, Knee
A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis
The purpose of this study is to determine the safety, tolerability, and activity of ICM-203, a recombinant adeno-associated viral (AAV) vector that expresses a therapeutic gene that promotes cartilage formation, reduces joint…
- Trial name
- NCT04875754
- Testing
- ICM-203
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- ICM Biotech Australia Pty Ltd.
Rheumatoid Arthritis
Outcomes of Biological Therapy on Rheumatoid Arthritis
Evaluate effect of biological therapy on activity of RA compared to usual DMARDs
- Trial name
- NCT05267431
- Testing
- Biological Drug
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
CAR-T Cell Therapy, Bispecific Antibodies
CAR-T Therapy: Safety, Efficacy, and Immune-Escape Mechanisms
The study is a biological, drug-related, non-interventional observational study with both retrospective and prospective components.
- Trial name
- OSR-CAR-T (NCT07915102)
- Where
- Italy
- Volunteers
- 225 people
- Sponsor
- Ciceri Fabio
Arthritis, Psoriatic
A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment
Observational, prospective and multicenter study in approximately 25 sites nationwide. The investigators participating in this study will be rheumatologists specializing in this pathology.
- Trial name
- PREVAIL (NCT03828045)
- Testing
- Apremilast
- Where
- 20 sites in Spain
- Volunteers
- 119 people
- Sponsor
- Amgen
Pancreatic Cancer
A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic…
- Trial name
- NCT00051467
- Testing
- TNFerade
- Where
- 25 sites in United States
- Sponsor
- GenVec
Alzheimer Disease
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
The study is a 24-week, randomized, double-blind, multi-site, placebo-controlled study in participants with mild cognitive impairment (MCI) or early dementia due to Alzheimer's disease (AD).
- Trial name
- PEGASUS (NCT03533257)
- Testing
- AMX0035
- Where
- 11 sites in United States
- Volunteers
- 95 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Psoriasis
Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients
The main goal of this study is to determine optimal cut-off values of adalimumab trough levels corresponding to good clinical response.
- Trial name
- NCT02147600
- Where
- 5 sites in Belgium
- Volunteers
- 82 people
- Sponsor
- University Hospital, Ghent
Lung Cancers
Bright Light Therapy on Sleep Health in Lung Cancer Patients
The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical…
- Trial name
- BLT (NCT07064395)
- Testing
- bright light
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Henry Ford Health System
Carcinoma, Renal Cell
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
The purpose of this study is to assess the safety and tolerability of TroVax® investigational vaccine injections when given as first or second line treatment in conjunction with subcutaneous low dose IL-2 to patients with locally…
- Trial name
- NCT00325507
- Testing
- TroVax, IL-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oxford BioMedica
Asthma
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with…
- Trial name
- AIRLYMPUS (NCT06676319)
- Testing
- Lunsekimig, Short-Acting Beta Agonists (SABA), Fluticasone/Salmeterol
- Where
- 221 sites in United States, Argentina and 20 more
- Volunteers
- 556 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible…
- Trial name
- MAINTAIN (NCT01692899)
- Volunteers
- 780 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.